Survival Similar in the Dialysis Population With High, Low PTH
Reported rates of low PTH and secondary hyperparathyroidism in the hemodialysis population are approximately 40% and 10%, respectively.
Secondary Hyperparathyroidism
Sodium Thiosulfate May Slow Vascular Calcification in Hemodialysis
No medication is currently approved to treat vascular calcification in this population.
Fracture Risk in CKD Not Higher With SGLT2 Inhibitors
Patients with CKD are vulnerable to fractures due to CKD mineral bone disorder.
Excessive Body Weight Lessens the Efficacy of Vitamin D Supplements
A round up of studies suggests it is difficult to increase serum total 25-hydroxyvitamin D levels enough to effectively lower elevated parathyroid hormone (PTH) levels in overweight patients with chronic kidney disease.
PTH Reduction Better With Etelcalcetide vs Cinacalcet in Hemodialysis Population
Intravenous etelcalcetide use remains limited by cost and reimbursement, investigators noted.
Calciphylaxis Diagnosis and Management in Primary Care
Author reviews calciphylaxis incidence, risk factors, pathogenesis, differential diagnoses, and treatment.
CKD-MBD Tied to Malnutrition-Inflammation Complex Syndrome
A new review highlights the need to simultaneously control CKD-MBD and MICS in patients receiving hemodialysis.
Therapies to Slow Vascular Calcification in CKD Explored
Promising therapies still need to be further evaluated in clinical trials.
Etelcalcetide vs Cinacalcet Treatment Adherence Examined
Secondary hyperparathyroidism remains uncontrolled in many patients with chronic kidney disease.
Earlier Calcimimetic Use May Allow Better PTH Control in Hemodialysis
Recent studies have shown the importance of starting treatment at lower phosphorus and PTH levels on long-term outcomes of SHPT.
- Loading...
Loading...
Next post in Secondary Hyperparathyroidism
Loading... 
Loading...